Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

John A. Hey¹ · Petr Kocis¹ · Jakub Hort^{2,3} · Susan Abushakra¹ · Aidan Power¹ · Martin Vyhnálek^{2,3} · Jeremy Y. Yu¹ · Martin Tolar¹

Published online: 12 November 2018
© Springer Nature Switzerland AG 2018

Correction to: CNS Drugs (2018) 32:849–861
<https://doi.org/10.1007/s40263-018-0554-0>

Page 856: Fig. 6 was an incorrect duplication of Fig. 5. The correct figure (Fig. 6) is given below.

Fig. 6 Ion-mobility spectrometry–mass spectrometry drift time as a function of mass/charge (m/z) after 24 h of incubation shows the profile of A β 42 oligomers with 1000-fold excess of 3-sulfopropanoic acid

The original article can be found online at <https://doi.org/10.1007/s40263-018-0554-0>.

✉ John A. Hey
john.hey@alzheon.com

¹ Alzheon, Inc, 111 Speen Street Suite 306, Framingham, MA 01701, USA

² International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic

³ Department of Neurology, Cognitive Center, 2nd Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czech Republic